Search

Your search keyword '"Multihartina, Pretty"' showing total 9 results
Start Over Author "Multihartina, Pretty"
9 results on '"Multihartina, Pretty"'

1. Immunogenicity and safety in healthy adults of full dose versus half doses of COVID-19 vaccine (ChAdOx1-S or BNT162b2) or full-dose CoronaVac administered as a booster dose after priming with CoronaVac: a randomised, observer-masked, controlled trial in Indonesia

Author

Sofiatin, Yulia, Suryadinata, Hendarsyah, Hartantri, Yovita, Sukandar, Hadyana, Indrati, Agnes Rengga, Murad, Chrysanti, Setiawaty, Vivi, Pangesti, Krisna Nur Andriana, Multihartina, Pretty, Khrisna, Citra Vravita, Ayuninda, Masayu Riela, Wicaksana, Pratama, Zhafira, Aqila Sakina, Sinto, Robert, Rusmil, Kusnandi, Sundoro, Julitasari, Watts, Emma, Nguyen, Cattram, Fadlyana, Eddy, Setiabudi, Djatnika, Kartasasmita, C B, Putri, Nina Dwi, Rezeki Hadinegoro, Sri, and Mulholland, Kim

Published
2023
Full Text
View/download PDF

2. Immunogenicity and Safety of Half-Dose Heterologous mRNA-1273 Booster Vaccination for Adults Primed with the CoronaVac ® and ChAdOx1-S Vaccines for SARS-CoV-2.

Author

Putri, Nina Dwi, Zhafira, Aqila Sakina, Wicaksana, Pratama, Sinto, Robert, Hanafi, Gryselda, Wiyono, Lowilius, Prayitno, Ari, Karyanti, Mulya Rahma, Naibaho, Murni Luciana, Febrina, Febrina, Sukandar, Hadyana, Setiawaty, Vivi, Mursinah, Mursinah, Putra, Ahmat Rediansya, Wibowo, Heri, Sundoro, Julitasari, Satari, Hindra Irawan, Oktavia, Dwi, Multihartina, Pretty, and Harbuwono, Dante Saksono

Subjects
BOOSTER vaccines, SARS-CoV-2, NEUTRALIZATION tests, COVID-19, COVID-19 vaccines, IMMUNE response
Abstract

Coronavirus disease 2019 (COVID-19) has been extensively researched, particularly with regard to COVID-19 vaccines. However, issues with logistics and availability might cause delays in vaccination programs. Thus, the efficacy and safety of half-dose heterologous mRNA should be explored. This was an open-label observational study to evaluate the immunogenicity and safety of half-dose mRNA-1273 as a booster vaccine among adults aged >18 years who underwent a complete primary SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) vaccination regimen with CoronaVac® and ChAdOx1-S. Adverse events (AEs), seropositivity rate, seroconversion, geometric mean titer (GMT) of SARS-CoV-2 antibodies, neutralizing antibodies, and T cells (CD4+ and CD8+) specific for SARS-CoV-2 were analyzed. Two hundred subjects were included in the final analysis, with 100 subjects in each priming vaccine group. Most of the AEs were mild, with systemic manifestations occurring between 1 and 7 days following vaccination. A significant difference was observed in the GMT and seropositivity rate following booster dose administration between the two groups. CD8+/CD3+, IFN (interferon)-producing CD8+, and TNF (tumor necrosis factor)-producing CD8+ cells showed significant increases in both groups. The administration of the half-dose mRNA-1273 booster is safe and effective in increasing protection against SARS-CoV-2 infection. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

3. Immunogenicity and safety in healthy adults of full dose versus half doses of COVID-19 vaccine (ChAdOx1-S or BNT162b2) or full-dose CoronaVac administered as a booster dose after priming with CoronaVac: a randomised, observer-masked, controlled trial in Indonesia

Author

Fadlyana, Eddy, primary, Setiabudi, Djatnika, additional, Kartasasmita, C B, additional, Putri, Nina Dwi, additional, Rezeki Hadinegoro, Sri, additional, Mulholland, Kim, additional, Sofiatin, Yulia, additional, Suryadinata, Hendarsyah, additional, Hartantri, Yovita, additional, Sukandar, Hadyana, additional, Indrati, Agnes Rengga, additional, Murad, Chrysanti, additional, Setiawaty, Vivi, additional, Pangesti, Krisna Nur Andriana, additional, Multihartina, Pretty, additional, Khrisna, Citra Vravita, additional, Ayuninda, Masayu Riela, additional, Wicaksana, Pratama, additional, Zhafira, Aqila Sakina, additional, Sinto, Robert, additional, Rusmil, Kusnandi, additional, Sundoro, Julitasari, additional, Watts, Emma, additional, and Nguyen, Cattram, additional

Published
2023
Full Text
View/download PDF

5. Immunogenicity and Safety in Healthy Adults of Full-Dose Versus Half Doses of COVID-19 Vaccine (ChAdOx1-S or BNT162b2) or Full-Dose CoronaVac Administered as a Booster Dose after Priming with Coronavac: A Randomized, Observer-Blinded, Controlled Trial Conducted in Indonesia

Author

Fadlyana, Eddy, primary, Setiabudi, Djatnika, additional, Putri, Nina Dwi, additional, Sofiatin, Yulia, additional, Suryadinata, Hendarsyah, additional, Hartantri, Yovita, additional, Sukandar, Hadyana, additional, Indrati, Agnes R., additional, Murad, Chrysanti, additional, Setiawaty, Vivi, additional, Nur A Pangesti, Krisna, additional, Multihartina, Pretty, additional, Khrisna, Citra Vravita, additional, Ayuninda, Masayu Riela, additional, Wicaksana, Pratama, additional, Zhafira, Aqila Sakina, additional, Shinto, Robert, additional, Kartasasmita, Cissy B., additional, Rusmil, Kusnandi, additional, Hadinegoro, Sri Rezeki, additional, Sundoro, Julitasari, additional, Watts, Emma, additional, Nguyen, Cattram D., additional, and Mulholland, Kim, additional

Published
2022
Full Text
View/download PDF

6. Microbiological and Clinical Aspects of Diphtheria-Confirmed Cases from Capital City of Indonesia, Jakarta, and Surrounding Areas in 2017

Author

Sunarno, Sunarno, primary, Puspandari, Nelly, additional, Sariadji, Kambang, additional, Febriyana, Dwi, additional, Febrianti, Tati, additional, Saraswati, Ratih Dian, additional, Maha, Masri S., additional, Handayani, Sarwo, additional, Lestari, Christina S.W., additional, Setiawaty, Vivi, additional, Fitriana, Fitriana, additional, Yuniar, Yuyun, additional, Pracoyo, Noer Endah, additional, Pradono, Julianti, additional, Siswanto, Siswanto, additional, Multihartina, Pretty, additional, Anggraeni, Nancy D., additional, Hidayati, Laili N., additional, Sukandar, Agus, additional, Safaat, Hadi, additional, and Karyanti, Mulya R., additional

Published
2021
Full Text
View/download PDF

7. Human immune responses elicited by an intranasal inactivated H5 influenza vaccine

Author

Ainai, Akira, primary, Riet, Elly, additional, Ito, Ryo, additional, Ikeda, Kazuyuki, additional, Senchi, Kyosuke, additional, Suzuki, Tadaki, additional, Tamura, Shin‐ichi, additional, Asanuma, Hideki, additional, Odagiri, Takato, additional, Tashiro, Masato, additional, Kurata, Takeshi, additional, Multihartina, Pretty, additional, Setiawaty, Vivi, additional, Pangesti, Krisna Nur Andriana, additional, and Hasegawa, Hideki, additional

Published
2020
Full Text
View/download PDF

8. IgA tetramerization improves target breadth but not peak potency of functionality of anti-influenza virus broadly neutralizing antibody

Author

Saito, Shinji, primary, Sano, Kaori, additional, Suzuki, Tadaki, additional, Ainai, Akira, additional, Taga, Yuki, additional, Ueno, Tomonori, additional, Tabata, Koshiro, additional, Saito, Kumpei, additional, Wada, Yuji, additional, Ohara, Yuki, additional, Takeyama, Haruko, additional, Odagiri, Takato, additional, Kageyama, Tsutomu, additional, Ogawa-Goto, Kiyoko, additional, Multihartina, Pretty, additional, Setiawaty, Vivi, additional, Pangesti, Krisna Nur Andriana, additional, and Hasegawa, Hideki, additional

Published
2019
Full Text
View/download PDF

9. Relationship of the quaternary structure of human secretory IgA to neutralization of influenza virus.

Author

Tadaki Suzukia, Akira Kawaguchi, Akira Ainai, Shin-ichi Tamura, Ryo Ito, Multihartina, Pretty, Setiawaty, Vivi, Krisna Nur Andriana Pangesti, Takato Odagiri, Masato Tashiro, and Hideki Hasegawa

Subjects
INFLUENZA research, INFLUENZA A virus, VIRAL vaccines, RESPIRATORY infections, HYPOVENTILATION, VACCINATION
Abstract

Secretory IgA (S-IgA) antibodies, the major contributors to humoral mucosal immunity to influenza virus infection, are polymeric Igs present in many external secretions. In the present study, the quaternary structures of human S-IgA induced in nasal mucosa after administration of intranasal inactivated influenza vaccines were characterized in relation to neutralization potency against influenza A viruses. Human nasal IgA antibodies have been shown to contain at least five quaternary structures. Direct and real-time visualization of S-IgA using high-speed atomic force microscopy (AFM) demonstrated that trimeric and tetrameric S-IgA had six and eight antigen-binding sites, respectively, and that these structures exhibited large-scale asynchronous conformational changes while capturing influenza HA antigens in solution. Furthermore, trimeric, tetrameric, and larger polymeric structures,which areminor fractions in human nasal IgA, displayed increased neutralizing potency against influenza A viruses comparedwith dimeric S-IgA, suggesting that the larger polymeric than dimeric forms of S-IgA play some important roles in protection against influenza A virus infection in the human upper respiratory tract. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results